Athira Pharma, Inc.
ATHA
$0.36
$0.01885.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 24.88M | 26.09M | 26.86M | 27.13M | 31.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.62M | 96.78M | 111.85M | 121.40M | 125.01M |
| Operating Income | -78.62M | -96.78M | -111.85M | -121.40M | -125.01M |
| Income Before Tax | -79.75M | -96.94M | -109.22M | -113.45M | -116.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.75 | -96.94 | -109.22 | -113.45 | -116.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.75M | -96.94M | -109.22M | -113.45M | -116.19M |
| EBIT | -78.62M | -96.78M | -111.85M | -121.40M | -125.01M |
| EBITDA | -77.65M | -95.81M | -110.88M | -120.43M | -124.04M |
| EPS Basic | -2.07 | -2.52 | -2.85 | -2.97 | -3.05 |
| Normalized Basic EPS | -1.23 | -1.51 | -1.75 | -1.89 | -1.94 |
| EPS Diluted | -2.07 | -2.52 | -2.85 | -2.97 | -3.05 |
| Normalized Diluted EPS | -1.23 | -1.51 | -1.75 | -1.89 | -1.94 |
| Average Basic Shares Outstanding | 154.64M | 153.92M | 153.32M | 152.86M | 152.48M |
| Average Diluted Shares Outstanding | 154.64M | 153.92M | 153.32M | 152.86M | 152.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |